LabGenomics Obtains Certification for Cell-Free DNA Extraction Reagent

[Asia Economy Reporter Jang Hyowon] LabGenomics has strengthened its competitiveness in the liquid biopsy market by securing cell-free DNA technology.

Molecular diagnostics specialist LabGenomics (CEO Jin Seunghyun) announced on the 13th that it has obtained domestic certification for an extraction reagent capable of securing high-purity cell-free DNA (cfDNA).

The LabGTM Cell-free DNA Isolation Kit, which has recently been certified, is an extraction reagent that can secure extremely small amounts of cell-free DNA present in blood with high purity and efficiency. Cell-free DNA refers to fragments of DNA that do not exist inside the cell nucleus but circulate in the blood, and it is considered a core technology in the liquid biopsy market.

In particular, the liquid biopsy field is receiving significant attention because it can be applied non-invasively and easily for diagnostic tests compared to tissue biopsy in areas such as early cancer diagnosis, prognosis prediction, and companion diagnostics, with cell-free DNA being the main analyte used.

Through this certification of the cell-free DNA extraction reagent, LabGenomics plans to develop various high value-added diagnostic services and products in the fields of early cancer diagnosis, prognosis, prediction, and companion diagnostics. Recently, the company signed a business agreement with DEXOM, which developed hereditary disease and cancer companion diagnostic panels, further enhancing its competitiveness in the liquid biopsy market.

A LabGenomics official stated, “This certification of the cell-free DNA extraction reagent can be used in various research and diagnostic fields that utilize cell-free DNA, including liquid biopsy. As we prepare to enter the rapidly growing U.S. liquid biopsy market, we will secure technology, develop high value-added diagnostic services, and establish a supply chain through CleaLab, achieving a stable market entry by combining all three factors.”

Meanwhile, liquid biopsy, which offers greater convenience and accuracy than conventional cancer tests, is gaining attention mainly in advanced countries such as the United States. While the in vitro diagnostics market grows by 4.8% annually, the liquid biopsy market is expanding dramatically by 24% each year.